Prof. Dr. Martin Storr
Prof. Dr. Martin Storr
Verified email at med.uni-muenchen.de
TitleCited byYear
The endogenous cannabinoid system protects against colonic inflammation
F Massa, G Marsicano, H Hermann, A Cannich, K Monory, BF Cravatt, ...
The Journal of clinical investigation 113 (8), 1202-1209, 2004
4592004
Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults
AJ Lucendo, J Molina-Infante, A Arias, U von Arnim, AJ Bredenoord, ...
United European gastroenterology journal 5 (3), 335-358, 2017
3112017
Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, HJ Woerle, ...
Gut 55 (2), 243-251, 2006
2642006
Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by 1H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and …
R Schicho, R Shaykhutdinov, J Ngo, A Nazyrova, C Schneider, ...
Journal of proteome research 11 (6), 3344-3357, 2012
1782012
Treatment of achalasia: botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up
HD Allescher, M Storr, M Seige, R Gonzales-Donoso, R Ott, P Born, ...
Endoscopy 33 (12), 1007-1017, 2001
1692001
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis
MA Storr, CM Keenan, H Zhang, KD Patel, A Makriyannis, KA Sharkey
Inflammatory bowel diseases 15 (11), 1678-1685, 2009
1602009
The endocannabinoid system controls food intake via olfactory processes
E Soria-Gómez, L Bellocchio, L Reguero, G Lepousez, C Martin, ...
Nature neuroscience 17 (3), 407, 2014
1592014
Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors
MA Storr, CM Keenan, D Emmerdinger, H Zhang, B Yüce, A Sibaev, ...
Journal of molecular medicine 86 (8), 925-936, 2008
1582008
The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract
F Massa, M Storr, B Lutz
Journal of molecular medicine 83 (12), 944-954, 2005
1542005
Distribution, function and physiological role of melatonin in the lower gut
CQ Chen, J Fichna, M Bashashati, YY Li, M Storr
World journal of gastroenterology: WJG 17 (34), 3888, 2011
1462011
Interstitial cells of Cajal integrate excitatory and inhibitory neurotransmission with intestinal slow-wave activity
S Klein, B Seidler, A Kettenberger, A Sibaev, M Rohn, R Feil, ...
Nature communications 4, 1630, 2013
1432013
Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long-term follow-up
M Storr, HD Allescher, T Rösch, P Born, N Weigert, M Classen
Gastrointestinal endoscopy 54 (6), 754-759, 2001
1362001
Eosinophilic colitis: epidemiology, clinical features, and current management
AA Alfadda, MA Storr, EA Shaffer
Therapeutic advances in gastroenterology 4 (5), 301-309, 2011
1352011
The endocannabinoid system and gut–brain signalling
MA Storr, KA Sharkey
Current opinion in pharmacology 7 (6), 575-582, 2007
1162007
Brain-gut interactions in IBS
J Fichna, M Storr
Frontiers in pharmacology 3, 127, 2012
1142012
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro
S Brand, J Dambacher, F Beigel, K Zitzmann, MHJ Heeg, TS Weiss, ...
American Journal of Physiology-Gastrointestinal and Liver Physiology 292 (4 …, 2007
1132007
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives
M Sobczak, M Sałaga, MA Storr, J Fichna
Journal of gastroenterology 49 (1), 24-45, 2014
1082014
The pathophysiology of chronic constipation
CN Andrews, M Storr
Canadian Journal of Gastroenterology and Hepatology 25 (Suppl B), 16B-21B, 2011
1052011
STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders
B Ottillinger, M Storr, P Malfertheiner, HD Allescher
Wiener Medizinische Wochenschrift 163 (3-4), 65-72, 2013
1022013
The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment
R Schicho, M Bashashati, M Bawa, D McHugh, D Saur, HM Hu, A Zimmer, ...
Inflammatory bowel diseases 17 (8), 1651-1664, 2010
992010
The system can't perform the operation now. Try again later.
Articles 1–20